Contains SILIPHOS® - patented natural hepatoprotector, lipophilic complex of silybin and phosphatidylcholine; does not cause adverse reaction. It is recognized as the most bioavailable form of silybin known today.
All natural products Santegra USA, including LiverPro™, have been manufactured from all natural remedies using high quality pure raw materials and technology that ensures all their beneficial properties intact, in strict compliance with GMP and TÜV regulations.
The exclusive Santegra®’s product – LiverPro™ is the most powerful natural formula for liver health.
The liver is the largest and one of the most complex organs in the human body. It plays a central role in nearly all body functions. The liver is the first line of defense, the key organ in the body’s detoxification system, the powerful filter, which cleanses blood by filtering out the toxins that assault the body on a regular basis. The liver filters over a liter of blood each minute!
The liver, due to the vital role it plays in metabolism, is particularly exposed to the harmful action of toxins. Many potentially harmful substances, such as alcohol, drugs and other toxins are metabolized by the liver and transformed into hydro-soluble derivatives for subsequent biliary extraction and removal from the body. For this reason the upkeep of the integrity of the liver cell is necessary for the safeguarding of health.
Very dangerous for the liver are free radicals, because they are involved as starters or intermediates in several biochemical reactions, which constitute a continuous risk factor for the integrity of the hepatocytes. (1)
Fortunately, you can take steps to protect your liver:
Reduce your exposure to toxins, especially alcohol, fried, processed and junk foods;
Try to avoid overeating, because it creates excessive work for the liver.
The unique LiverPro™ formula will help you to normalize and maintain liver functions.
Per one capsule:
SILIPHOS® (Milk Thistle Phytosome® - silybin (from Silybum Marianum L. Gaertn.) phosphatidylcholine complex) (contains 40 mg sylibin, 80 mg phosphatidylcholine) –120 mg.
Take 3 capsules twice daily with a large glass of water with food as a dietary supplement.
Research Brief As demonstrated by pharmacokinetic studies in comparison with free silybin and silymarin, SILIPHOS® represents the most absorbable form of silybin known until now.
After oral administration of 200 mg/kg of silybin, the plasma levels of this drug and its conjugated metabolites were below the analytical detection limit, while, after oral administration of SILIPHOS® (200 mg/kg as silybin) the plasma levels of silybin (free and total) were easily measurable (Fig. 2).(animal studies)
After oral administration of SILIPHOS®, the biliary elimination of silybin was not complete at 24 h and accounted for about 3.7% of the administered dose. After administration of uncomplexed silybin, biliary elimination accounted for only 0.001%. (Fig. 3).
The compound was rapidly excreted in urine where at 72 h the amount recovered accounted for about 3.3%. After administration of uncomplexed silybin, urinary elimination accounted for only 0.032%. (Fig.4).
SILIPHOS® shows the same pharmacokinetic profile in man. After oral treatment, the bioavailability in healthy volunteers, in cholecystectomised patients or in patients suffering from hepatic cirrhosis is comparable to that demonstrated in animal models. (Fig. 2, 3, 4). (2, 10,11)
SILIPHOS® demonstrated a superior bioavailability which, as calculated for cumulative biliary excretion, resulted to be about 10-fold higher than that of the extract. (4)
The improvement of the oral bioavailability for SILIPHOS® is mainly dependent on a marked increase of its absorption in the gastrointestinal tract, most likely due to the lipophilic character of the complex.
SILIPHOS® is to be considered a natural vehicle of silybin, the active botanical ingredient. SILIPHOS® allows silybin to reach the target organ, the liver, in concentrations which are reported to be effective in several models of liver intoxication. (9)
Clinical studies have been performed to evaluate the properties of SILIPHOS® in subjects with impairment of liver function.
Vailati et al performed an open randomized trial on 65 patients suffering from chronic persistent hepatitis. The protective effects of SILIPHOS® increased with the dose and 240 mg/die p.o. (as silybin) resulted to be the mean therapeutic dose whereas 360 mg/die p.o. (as silybin) was recommended for the treatment of the severe resistant form of hepatitis or during the initial management of the patients. (5)
In a study carried out on 232 patients with alcoholic, acute viral or iatrogenic hepatitis, the subjects have been treated with 240 or 360 mg/die p.o. (as silybin) for 120 days. No side effects have been observed and SILIPHOS®, in comparison with placebo, showed its ability to improve liver condition. (6)
In a short-term pilot study performed on 20 patients with chronic active hepatitis, the biochemical parameters related to hepatocellular damage and necrosis were significantly reduced after 7 days of treatment with 240 mg/die p.o. (as silybin). (Fig. 1) (7)
A 2-month study on 8 patients complaining of chronic active hepatitis has shown the ability of SILIPHOS® to reduce serum MDA concentration and to increase galactose elimination by the liver. (8)
1. Schiff L., Schiff E.R., "Disease of the liver", V ed., J. B. Lippincott Co., Philadelphia, 1982.
2. Morazzoni P., Bombardelli E., Fitoterapia 50, 1 (1995).
3. Morazzoni P., Magistretti M.J., Giachetti C., Zanolo G., Eur. J. Drug Metabol. Pharmacokinet. 17, 39 (1992).
4. Morazzoni P., Montalbetti A., Malandrino S., Pifferi G., Eur. J. Drug Metabol. Pharmacokinet. 18, 289 (1993).
5. Vailati A., Aristia L., Sozzè E., Milani., Inglese V., Galenda P., Bossolo P.A., Ascari E., Lampertico M., Comis S., Marena G., Fitoterapia 64, 219 (1993).
6. Marena C., Lampertico M., Planta Med. 57, suppl., A124 (1991).
7. Buzzelli G., Moscarella S., Giusti A., Duchini A., Marena C., Lampertico M., Int. J. Clin. Pharmacol. Ther. Toxicol. 31, 456 (1993).
8. Moscarella S., Giusti A., Marra F., Marena C., Lampertico M., Relli P., Gentilini P., Buzzelli G., Curr. Ther.Res. 53, 98 (1993).
9. Conti M., Malandrino S., Magistretti M.J., Jpn J. Pharmacol. 60, 315 (1992).
10. Orlando R., Fragasso A., Lampertico M., Marena C., Med. Sci. Res. 19, 827 (1991).
11. Barzaghi N., Perucca E., Pifferi G., Crema A., Flavonoids in Biology and Medicine, Singapore, November 13-17, 1989.